Results 121 to 130 of about 176,283 (306)

Greetings from below the aortic arch! The paradigm of cardiac paraganglioma. [PDF]

, 1996
Heufelder, Armin E., Hofbauer, Lorenz C.
core   +1 more source

Investigation of the Mechanism of Cinnamaldehyde in Irritable Bowel Syndrome Based via Network Pharmacology, Molecular Docking, and Animal Experiments

Pediatric Discovery, EarlyView.
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu, Boqing Xu, Chunfang Dai, Yayan Pang, Zhifang Dong   +4 more
wiley   +1 more source

Pulsed Electromagnetic Fields: A Novel Attractive Therapeutic Opportunity for Neuroprotection After Acute Cerebral Ischemia

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objectives Acute cerebral ischemia is characterized by several pathological processes evolving during time, which contribute to the final tissue damage. Secondary processes, such as prolonged inflammatory response, impaired mitochondrial function and oxidative stress, are responsible for the progression of brain injury to the peri‐infarct area,
Fioravante Capone, Simona Salati, Fabrizio Vincenzi, Micaela Liberti, Giorgio Aicardi, Francesca Apollonio, Katia Varani, Ruggero Cadossi, Vincenzo Di Lazzaro   +8 more
wiley   +1 more source

Case of extragonadal germ cell tumor mimicking left adrenal tumor. [PDF]

Urol Case Rep, 2023
Ito H, Nakane K, Yamada T, Kobayashi K, Miyazaki T, Koie T.   +5 more
europepmc   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

Phytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Primary Retroperitoneal Mucinous Cystic Neoplasm Involving Adrenal Gland

The Kaohsiung Journal of Medical Sciences, EarlyView.
Di‐Ping Yu, Xiao‐Long Liu, Xin‐Yu Li   +2 more
wiley   +1 more source

Safety of 8‐Week Administration With Ashwagandha (Withania somnifera) Root Extract in Adults With Stress and Anxiety: Findings From a Prospective, Randomized, Multi‐Center, Double‐Blinded, Placebo‐Controlled Study

Phytotherapy Research, EarlyView.
ABSTRACT Ashwagandha (Withania somnifera) has been recognized for enhancing physical strength, mental well‐being, and overall vitality. Despite its long‐standing use across generations, some clinical reports have noted occasional adverse events. This study compared the safety and tolerability of Ashwagandha Root Extract (ARE) in healthy adults.
Ketan Pakhale, Jaising Salve, John Ademola, Jose Parraca, Deepak Langade   +4 more
wiley   +1 more source

Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity

Periodontology 2000, EarlyView., 2023
Abstract Noncommunicable diseases (NCDs) are multifactorial, long‐term, chronic conditions that represent a burden to health‐care systems worldwide as they can only be controlled rather than cured; hence, they require long‐term care. With the exponential increase in NCDs, the occurrence of individuals presenting with more than one chronic disease is ...
Crystal Marruganti, Jean E. Suvan, Francesco D'Aiuto   +2 more
wiley   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source